GiRAF Trial
-
Dr
Raymond Hu
Project Details
General vs. Regional Anaesthesia on arteriovenous Fistula patency (GiRAF): a randomised controlled pilot and feasibility trial
More than 2500 Australians require chronic haemodialysis for their kidney failure annually. Native arteriovenous fistula is currently the preferred surgical procedure for haemodialysis. However, many types of anaesthetic techniques can facilitate this procedure, each with differing effects on the patient's long term outcomes.
Prior studies have shown the benefits of brachial plexus block anaesthetic technique on increasing arteriovenous fistula success when compared to local anaesthetic.
Therefore, current general strategies employed for this surgery are brachial plexus block and general anaesthetic. However, there is no current randomised control trials comparing the benefits of brachial plexus block to general anaesthetic. This is what the GiRAF study aims to address.
Aims:
- Establish a pilot study to test the feasibility of recruiting sufficient patients to participate in the randomised control trial, with possibility for future large scale expansion
- Provide evidence from the randomised control trial comparing branchial plexus block to general anaesthetic on 12-week arteriovenous fistula patency
- Establish feasibility for collecting multiple definitions for fistula success (patency)
The outcome of this study will help establish the best practice procedure and improve outcomes for chronic kidney disease patients undergoing haemodialysis requiring fistula formation.
Researchers
Chief Investigators
Dr Raymond Hu
Professor Philip Peyton
Dr Andrea Viecelli
Associate Professor Peter Mount
Associate Professor Jason Chuen
Associate Investigators
Dr Soon Teoh - Site Principle Investigator
Dr Andrew Marriott - Site Principle Investigator
Dr Basel El-Behesy - Site Principle Investigator
Ms Sofia Sidiropoulos - Research Manager
Ms Anurika De Silva - Statistical Analyst
Funding
Darcy Price ANZCA Regional Research Award